Drug Profile
AMAP 102
Alternative Names: AMAP102Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AnaMar AB
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Musculoskeletal pain
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in United Kingdom (PO)
- 31 Jul 2015 Phase-II development is ongoing for Musculoskeletal pain (associated with osteoarthritis) in Europe
- 30 Oct 2014 Top-line efficacy and adverse events data from a phase II trial in Musculoskeletal pain (pain associated with osteoarthritis) released by AnaMar